Conclusion
S. boveanum treatment significantly ameliorated cholestatic hepatic injury via anti-oxidative and anti-inflammatory effects.
Methods
Five groups of Sprague-Dawley rats including Sham and four BDL groups were assigned to receive vehicle (BDL-V) or ethanolic extract of S. boveanum at 100 (BDL-SE 100), 200 (BDL-SE 200) and 500 (BDL-SE 500) mg/kg/day for seven days.
Objective
The current study assessed hepatoprotective effects of Sargassum boveanum (S. boveanum) in cholestatic rats. To induce cholestasis, bile duct ligation (BDL) was utilized. Materials and
Results
BDL group receiving the vehicle (BDL-V) had substantially increased blood levels of alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, total, and indirect bilirubin in comparison to the sham group. S. boveanum significantly decreased these variables compared to the BDL-V group. Hepatic malondialdehyde and tumor necrosis factor-α (TNF-α) level, and nuclear factor kappa light chain enhancer of activated B cells (NF-κB) and TNF-α gene expression were higher in BDL-V rats compared to the sham group but these were reduced markedly in BDL groups receiving S. boveanum in comparison to the BDL-V group. BDL-V group had a significantly lower hepatic glutathione value, glutathione peroxidase (GPx) and superoxide dismutase (SOD) activity and gene expression of SOD, GPx, Nrf2, HO-1 in comparison to the sham group. S. boveanum prevented the decrease of these variables. The histopathological assay showed marked bile ducts proliferation, portal inflammation, and hepatocellular damage in the BDL-V group and S. boveanum administration remarkably reduced hepatic injury. Gas chromatography-mass spectroscopy (GC-MS) analysis revealed that S. boveanum ethanolic extract contained 39 active compounds.